OR WAIT null SECS
Maryanne Quinn, President, Integrated Submission Strategies (ISS), is Chair of the TMF RM Communication Team and has over 25 years of experience in the Life Sciences Industry and can be reached at ISS.Quinn@verizon.net
Fran Ross, Principal Consultant, Clin/Reg Optimization | Paragon Solutions, is Chair of the TMF RM Survey Team and Lead for Asia Pacific SubTeam and can be reached at firstname.lastname@example.org
Karen Redding, Global Business Development Director of Phlexglobal, is the Co-Chair of the TMF Reference Model Group and can be reached at email@example.com
One of the many activities across the clinical development cycle that is non-negotiable is the creation, collection, management, and storage of the documents that are contained in the Trial Master File.
One of the many activities across the clinical development cycle that is non-negotiable is the creation, collection, management, and storage of the documents that are contained in the Trial Master File (TMF). The TMF contains those essential documents that individually and collectively permit the evaluation of the conduct of a trial and the quality of the data produced. These documents serve to demonstrate the compliance of the investigator, sponsor, and monitor with the standards of good clinical practice (GCP) and with all applicable regulatory requirements.1
All sponsors—whether an individual, company, institution, or organization—and investigators conducting clinical trials in life sciences (i.e. pharmaceutical, biotechnology, or device trials) are required to maintain documentation for each clinical trial. Regulatory guidance, such as ICH E6 section 8, addresses only a minimum subset of documents that are commonly retained; there are significantly more documents in a TMF, as shown in Figure 1.
Historically, there has been no comprehensive, common industry model for a TMF and, therefore, each trial sponsor has its own unique TMF structure as defined by its standard operating procedures (SOPs). This is a highly inefficient way for the industry to work for many reasons, including:
Records and information exchange between partners, in acquisitions, and in outsourced trials is extremely cumbersome. Information searches are laborious, files are frequently restructured, and productive knowledge sharing is significantly hampered—major inhibiting factors for successful collaboration. Regulators consistently find different terminology and file structure —sponsor-to-sponsor—creating inefficiency and a higher degree of variability during inspection.
To address the gap in TMF standards, in 2009 the TMF Reference Model (RM) team was initially created within the Document and Records Management Community of the Drug Information Association (DIA) to develop a standardized taxonomy that outlines the clear definition and organization of TMF content using standard nomenclature. As of early 2013, the TMF Reference Model team is composed of over 330 representatives from more than 180 life science companies, CROs, consultancies, technical vendors, industry groups, healthcare, academia, not-for-profit/ NGO, and regulatory agencies spread globally from the United States to Australia. The Asia-Pacific subgroup was a significant addition in 2012, and to date there are already 25 members in the group.
The Model details the generic content that individually and/or collectively permit the evaluation of the conduct of a clinical trial and the quality of the data produced, in accordance with industry opinion and best practices. Company-specific documents, dictated by SOPs, can be added. The Model is a reference for the industry and is not considered mandatory, but rather an opportunity for standardization across the industry. The Model can be adapted to an electronic or paper TMF. It does not endorse, nor require, any specific technology for application. The Model can be downloaded free from the DIA website at: http://www.diahome.org/en/News-and-Publications/Publications-and-Research/EDM-Corner.aspx.
Version 1.0 of the Model, first released in June 2010, was updated in February 2011 (V1.1) and again in December 2011 (V1.2), based on broad feedback provided from end users and reviewers, including the UK and US regulatory agencies MHRA and FDA. Version 2.0 of the Model, released in June 2012, included numerous new aspects:
A subgroup of the TMF RM Team developed the first industry benchmark TMF surveys. The intent was to gather data on the industry’s current TMF processes and to develop benchmarks for quality and effectiveness improvements, both in paper and electronic TMFs. The first survey was completed in Q3 2010, and the second survey followed in Q1 2012. The 2012 survey provides valuable data from 168 respondents (57% of which were sponsors) on current TMF practices. (Note: The 2014 TMF survey is currently in progress, and can be found at https://www.surveymonkey.com/s/WZHSL2P).
Electronic trial master files: The 2012 data indicates a significant growth in the number of organizations transitioning to eTMF. For inspection, 32% of survey respondents maintain paper TMFs, down from 50% in the corresponding 2010 survey. While there is only a modest increase in the number of respondents using eTMFs for inspection (8%), the increase in the number of respondents maintaining a combination of paper and electronic TMFs was significant—48% in 2012, compared to just 27% in 2010.
The 2012 data also shows an overall trend to implementing eTMFs. The 2012 survey reveals that 28% of the respondents are currently using an eTMF, and 57% are in the process of planning, building, or evaluating eTMF. In the 2010 data, only 45% of respondents were actively building or evaluating eTMF. In the 2012 survey, only 3% of respondents replied that they are not considering eTMF.
Process Efficiency: The 2012 survey results comparing process efficiency when using paper TMF vs. electronic TMF provide a compelling case for transition to a eTMF.
The 2012 data indicates further efficiencies can be realized when the Model is applied in an eTMF.
The folllowing are case studies of efforts that provide insight and examples of how the Model has been implemented.
Problem statement: The clinical trial industry has extensive experience in managing paper-based TMFs. The interpretation of what defines an essential document has been the scrutiny of many using the ICH GCP E8 Guidelines as a reference point. For CROs, such as Covance, this meant considering different interpretations of the reference plus ensuring the flexibility to include anything considered part of a sponsor’s interpretation of the reference. The TMF Index became lengthy, standards across studies were lost, and developing a TMF Index for a new study would be similar to starting from scratch each time. This loss of efficiency at study start was critical.
Solution: In 2011, there was a shift in how the industry was looking at eTMFs. Covance was ready to build a new TMF to support their needs and ensure it was broad and adaptive for their sponsors. We investigated required changes, and updated our internal filing processes. The new TMF RM from the DIA Working Group was released in June 2010 and its internal project started the following January.
Consistency with data governance and regulatory standards, controlling costs, and satisfying sponsors’ needs required a standard and efficient way of filing essential documents while ensuring the TMF was audit-ready. We aligned leaders to each of the 11 TMF RM zones. The zone leaders systematically conducted an analysis of how they were historically filing within the zone, comparing it to the TMF RM, and considered how they wanted to file in the future. This effort was not trivial, nor should be underestimated.
In early 2011, approximately 65-plus employees globally, representing all disciplines of clinical development operations, worked together to map the historical TMF Index to the TMF RM, categorizing each artifact (value-added or wet-ink) and ultimately developed the future state TMF Index. Looking across the operations, Phase I to Phase IV, each zone obtained agreement from key stakeholders. Critically important to the effort was ensuring buy-in from the various parties responsible for translating these processes to the sponsors.
Result: While the work may not have been trivial (~12 months and ~65 people), it was an important milestone in building the TMF structure that would eventually become our new eTMF system. The new TMF Index is being used with all in-flight paper studies and within the eTMF system launched in September 2012. Through the work of this team, we removed ~72 business file documents, resulting in a significant reduction of filing work effort. We continue to evaluate the TMF RM updates as they are released. Our process evaluates the updates and determines whether to incorporate the updates into our TMF Index via a change control review board, which implements changes for the TMF Index and SOPs, in addition to the eTMF system configuration.
Pfizer is currently implementing a new eTMF process and software solution where the focus has been very much on quality and standards. At any point in time, Pfizer has hundreds and hundreds of clinical trials ongoing in every size, shape, and form. Therefore, having consistency of quality and standards is crucial to the success of managing and demonstrating control of a study TMF. Implementing a single eTMF repository has beneficial outcomes to multiple aspects of clinical trial management.
Among the many benefits to using a central single eTMF repository are the ability to present a cohesive and centrally accessible TMF to study teams, auditors and inspectors in any geographical location, as well as interoperability with other systems and supporting downstream activities. This eliminates the need for:
Getting content out is equally as important as getting content in; utilizing standards in the form of metadata not only ensures consistency in what is put into the eTMF but makes the possibility of retrieving the content more robust. Additionally, interoperability of a single eTMF with other systems (i.e., CTMS) brings huge benefits in the reusability of data and elimination of transcriptional errors, as well as the need for extensive, expensive, and duplicative QC processes. When managing several hundred studies and working with many external collaborators, the TMF standards facilitate consistency and transparency in control and management of a clinical trial. In the construction of the Pfizer TMF Document List, we utilized and mapped to the TMF RM, which enables alignment with the industry-wide RM and consistent use of metadata.
Improved process efficiency: How does the TMF RM facilitate process efficiency?:
The Case for the TMF RM becoming a standard: Taking all of the facts into account, should the TMF RM become an industry standard? A standard can be defined as “something considered by an authority or by general consent as a basis of comparison; an approved model.”
An effective standard includes the following key features:
Many standards fail due to lack of compliance, communication to the relevant community, lack of compatibility with reality, and an inability to map to the current common situation. If the Model is to become a standard, then these pitfalls need to be avoided.
The case studies and our 2010 and 2012 surveys provide compelling data and a clear case for establishing a common model for the organization and management of the Trial Master File. Standards promote interoperability, increase quality, and reduce effort for all clinical trials and are foundational for transition to an electronic TMF, which provides significant process efficiencies in the conduct of clinical trials.
As the Model continues to evolve through implementation and improvement, there is an opportunity to offset some of the challenges that industry is currently facing. Establishing consensus and working as a group rather than individually will ensure that the Model is an enduring standard that continues to provide significant value to all participants in the R&D process.
Maryanne Quinn, President, Integrated Submission Strategies (ISS), is Chair of the TMF RM Communication Team, email: [email protected]; Karen Redding, Global Business Development Director, Phlexglobal, is the Co-Chair of the TMF Reference Model Group; email: [email protected]; Fran Ross, Principal Consultant, Clin/Reg Optimization, Paragon Solutions, is Chair of the TMF RM Survey Team and Lead for Asia-Pacific SubTeam, email: [email protected]
1. ICH Guideline for Good Clinical Practice, E 6, Section 8
2. Rammell Consulting, Ltd.
3. Jamie Marie Toth, Director, Business Process & Solutions/eTMF Business Owner - Covance Inc.
[email protected] - 609-452-4221
4. Martin Thorley, Associate Director, TMF Content Integration Lead, Pfizer Ltd - [email protected] -
+44 (0)1304 648181